Stocks · News reference
Filed: 2026-10-30 AccNo: 0001104659-26-120457 Size: 3 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 3.02: Unregistered Sales of Equity Securities Item 3.03: Material Modifications to Rights of Security Holders Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 5.07: Submission of Matters to a Vote of Security Holders Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Pelthos Therapeutics has entered into a definitive agreement to merge with Castle Creek Biosciences, a late-stage gene therapy company, to expand its portfolio into rare skin disease treatments.
Pelthos Therapeutics has raised CEO Scott Plesha's base salary and target bonus opportunity while amending his employment agreement to include prorated bonus provisions upon termination.
Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday. Jin Medical
Lake Street analyst Thomas Flaten maintains Pelthos Therapeutics (AMEX:PTHS) with a Buy and lowers the price target from $50 to $40.